ArticleFrontiers in pharmacology2025

Adverse events of hepatic anti-fibrotic agents in phase 3 and above clinical trials: a descriptive analysis of the WHO-VigiAccess database.

Yuwei Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.